NCT02087111 - Telaprevir in Genotype 3 HCV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 1, 2016

Study Completion Date

November 1, 2016

Conditions

Hepatitis C

Interventions

DRUG

Telaprevir

375 mg film coated tablets

DRUG

40 Kd Pegylated interferon alfa 2a

180 µg in pre-filled syringe for sub-cutaneous injection

DRUG

Ribavirin

200 mg tablets

Trial Locations (4)

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

E1 1BB

Barts Health NHS Trust, London

SW17 0QT

Ste Georges Healthcare NHS Trust, London

NG7 2UH

Nottingham University Hospitals Trust, Nottingham

All Listed Sponsors

collaborator

Janssen-Cilag Ltd.

INDUSTRY

collaborator

Barts & The London NHS Trust

OTHER

collaborator

St George's Healthcare NHS Trust

OTHER

collaborator

Bradford Teaching Hospitals NHS Foundation Trust

OTHER_GOV

collaborator

Nottingham University Hospitals NHS Trust

OTHER

lead

Queen Mary University of London

OTHER